Tagged with Sanofi

Turkey * Dr Fabrizio Guidi has left his role as country chair & general manager Rx of Sanofi Turkey and is currently Sanofi’s general manager of diabetics and cardiovascular for Germany, Switzerland and Austria. From January 2019 Dr Guidi will become Sanofi’s general manager primary care GBU Germany, Switzerland and Austria and country…

France Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses due to competition to its diabetes and cardiovascular franchises. The growth is largely down to Dupixent — a drug for use…

Algeria Haissam Chraiteh, country chair for Sanofi Algeria, expands on Sanofi’s ground-breaking foothold in Algerian local production, and how its partnership with the authorities ultimately manifests itself in better provision for patients.   What are your impressions of the Algerian market after two years here as country chair for Sanofi Algeria?…

Algeria The Top 20 Pharma Companies in Algeria based on sales in 2017. Sanofi is way out in front with USD 458.6 million in sales, followed by local champion El Kendi with USD 254.1 million and Danish diabetes specialist Novo Nordisk with USD 239.1 million.

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

Brexit Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms ever closer, industry professionals fervently speculate on how it will affect the country’s position as one of the world’s great…

Portugal Francisco del Val, recently nominated general manager of the business unit Sanofi Genzyme and country head of Sanofi Portugal, has two decades’ experience in the pharma industry. In his first interview in Portugal, Francisco shares with us his priorities and his vision, highlighting the importance of diversification, and innovation through…

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

Ecuador The top 20 pharma companies in Ecuador in 2017, ranked by value, for both the retail and public markets. Argentinian firm Roemmers leads the way in the retail market, followed by global players Bayer and Sanofi. In terms of Ecuador’s public market, the top three companies are global giants Roche,…

UK Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance of vaccine R&D and production in the UK.   We have a broad portfolio, from the very first vaccine that…

India Jean-Pierre Baylet, country head for India and cluster head for South Asia at Sanofi Pasteur, provides insights into the progress and room for improvement that lie ahead for India’s immunization program, while highlighting Sanofi’s unrivalled commitment to protecting the Indian population from vaccine- preventable diseases like polio and flu as…

Latvia The top 20 companies in the Latvian pharmaceutical market for 2017, sorted by total value and market share, with data on year-on-year growth. American giant AbbVie ranks first, with an almost six percent market share and astounding 65 percent year-on-year growth, followed by TEVA and Sanofi.